The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer

  • Ramalingam S
  • Khuri F
12Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

The treatment of older patients with advanced non-small cell lung cancer (NSCLC) represents a considerable challenge for physicians. A patient ’s suitability for chemotherapy is frequently based solely on chronologic age; as a consequence, older patients with NSCLC are less likely to receive standard chemotherapy than younger patients. Although age-related factors, such as comorbid illness, should be taken into consideration when assessing a patient ’s suitability for treatment, fit and functionally independent older patients should be considered candidates for standard chemotherapy. The taxanes are widely used in the treatment of advanced-stage NSCLC and are well tolerated in older patients. The efficacy of both paclitaxel and docetaxel has been studied in older patients and appears to be comparable with that seen in younger patients either as monotherapy or in combination with a platinum compound as first-line therapy. In addition to the available evidence, prospective evaluation of novel agents in elderly-specific or -enriched studies is necessary to guide the treatment of older patients with NSCLC.

References Powered by Scopus

Cancer statistics, 2008

10417Citations
N/AReaders
Get full text

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

5506Citations
N/AReaders
Get full text

Underrepresentation of patients 65 years of age or older in cancer- treatment trials

1961Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy

108Citations
N/AReaders
Get full text

A review of the management of elderly patients with non-small-cell lung cancer

83Citations
N/AReaders
Get full text

Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells

35Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ramalingam, S. S., & Khuri, F. R. (2009). The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer. The Oncologist, 14(4), 412–424. https://doi.org/10.1634/theoncologist.2008-0190

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

67%

Professor / Associate Prof. 3

25%

Researcher 1

8%

Readers' Discipline

Tooltip

Nursing and Health Professions 4

33%

Medicine and Dentistry 4

33%

Agricultural and Biological Sciences 3

25%

Biochemistry, Genetics and Molecular Bi... 1

8%

Save time finding and organizing research with Mendeley

Sign up for free